Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

People with HIV may experience homelessness when they’re shunned by their families or asked to leave their homes, one ...

Fungal infections, particularly in immunocompromised individuals, are responsible for nearly four million deaths annually—however, current treatments are limited and are frequently ineffective. Now, ...

Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV ...

Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

The medication, Lenacapavir, is said to have shown exceptional promise in clinical trials, and some of the research is being conducted here in Houston.

Staffers at the remnants of the United States Agency for International Development (USAID), the foreign aid agency dismantled ...

Here are seven new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in alphabe ...